Table 2 Clinicopathologic feature of breast cancer patients [n(%)].
From: The diagnostic value of DNA repair gene in breast cancer metastasis
Variable | Total n = 206 | Control (non metastasis) n = 103 | Metastasis n = 103 | P-value |
|---|---|---|---|---|
Age | ||||
< 50 | 98 | 47 (45.6) | 51 (49.5) | 0.577† |
≥ 50 | 108 | 56 (54.4) | 52 (50.5) | |
ER | ||||
Negative | 79 | 33 (32.0) | 46 (44.7) | 0.032* |
Positive | 127 | 70 (68.0) | 57 (55.3) | |
PR | ||||
Negative | 108 | 46 (44.7) | 62 (60.2) | 0.714* |
Positive | 98 | 57 (55.3) | 41 (39.8) | |
HER2 | ||||
−/+ | 138 | 68(66.0) | 70(68.0) | 0.001* |
+++ | 68 | 35 (34.0) | 33 (32.0) | |
E-Cad | ||||
Negative | 24 | 14 (13.6) | 10 (9.7) | < 0.001* |
Positive | 182 | 89 (86.4) | 93 (90.3) | |
P53 | ||||
Negative | 107 | 58 (56.3) | 49 (47.6) | 0.757* |
Positive | 99 | 45 (43.7) | 54 (52.4) | |
Ki67 | ||||
< 20 | 54 | 31 (30.1) | 23 (22.3) | < 0.001* |
≥ 20 | 152 | 72 (69.9) | 80 (77.7) | |
Molecular subtypes | ||||
Luminal A | 36 | 22 (21.4) | 14 (13.6) | 0.064† |
Luminal B | 55 | 27 (26.2) | 28 (27.2) | |
Luminal HER2 | 45 | 25 (24.3) | 20 (19.4) | |
HER2-enriched | 23 | 10 (9.7) | 13 (12.6) | |
Basal-like | 47 | 19 (18.4) | 28 (27.2) | |
Lymph node metastasis | ||||
0 | 71 | 49 (47.6) | 22 (21.4) | 0.000† |
1 ~ 3 | 43 | 27 (26.2) | 16 (15.5) | |
4 ~ 9 | 38 | 12 (11.7) | 26 (25.2) | |
≥ 10 | 54 | 15 (14.6) | 39 (37.9) | |
Pathological type | ||||
Carcinoma in situ | 11 | 7 (6.8) | 4 (3.9) | 0.405† |
Non-specific invasive carcinoma | 193 | 95 (92.2) | 98 (95.1) | |
Invasive special type carcinoma | 2 | 1 (1.0) | 1 (1.0) | |
Tumor size | ||||
< 2 cm | 60 | 33 (32.0) | 27 (26.2) | 0.819† |
≥ 2 cm and ≤ 5 cm | 120 | 55 (53.4) | 65 (63.1) | |
> 5 cm | 26 | 15 (14.6) | 11 (10.7) | |
WHO grade | ||||
I | 9 | 8 (7.8) | 1 (1.0) | 0.465† |
II | 128 | 60 (58.3) | 68 (66.0) | |
III | 69 | 35 (34.0) | 34 (33.0) | |
